| Camostat mesilate (N = 77) | Placebo (N = 76) | Total (N = 153) |
---|---|---|---|
Number of patients with | |||
 Any adverse events | 25 (32.5) | 31 (40.8) | 56 (36.6) |
 Any serious adverse events | 1 (1.3) | 0 | 1 (0.7) |
 Any adverse events that led to discontinuation of treatment | 2 (2.6) | 0 | 2 (1.3) |
 Any adverse drug reactions | 9 (11.7) | 7 (9.2) | 16 (10.5) |
 Serious adverse drug reactions | 0 | 0 | 0 |
 Adverse drug reactions that led to discontinuation of treatment | 2 (2.6) | 0 | 2 (1.3) |
 Adverse events or adverse drug reactions resulting in death | 0 | 0 | 0 |
Adverse drug reactions by system organ class/preferred term | |||
 Gastrointestinal disorders | 4 (5.2) | 5 (6.6) | 9 (5.9) |
  Abdominal discomfort | 1 (1.3) | 1 (1.3) | 2 (1.3) |
  Constipation | 1 (1.3) | 0 | 1 (0.7) |
  Diarrhea | 2 (2.6) | 1 (1.3) | 3 (2.0) |
  Nausea | 0 | 1 (1.3) | 1 (0.7) |
  Stomatitis | 0 | 1 (1.3) | 1 (0.7) |
  Vomiting | 0 | 1 (1.3) | 1 (0.7) |
 Hepatobiliary disorders | 1 (1.3) | 1 (1.3) | 2 (1.3) |
  Hepatic function abnormal | 1 (1.3) | 1 (1.3) | 2 (1.3) |
 Laboratory tests | 3 (3.9) | 2 (2.6) | 5 (3.3) |
  Alanine aminotransferase increased | 1 (1.3) | 2 (2.6) | 3 (2.0) |
  Aspartate aminotransferase increased | 0 | 1 (1.3) | 1 (0.7) |
  Blood potassium increased | 2 (2.6) | 0 | 2 (1.3) |
  Blood alkaline phosphatase increased | 0 | 1 (1.3) | 1 (0.7) |
 Skin and subcutaneous tissue disorders | 1 (1.3) | 1 (1.3) | 2 (1.3) |
  Drug eruption | 1 (1.3) | 0 | 1 (0.7) |
  Rash papular | 0 | 1 (1.3) | 1 (0.7) |